BriaCell Therapeutics Corp. (BCTX): Shareholders' Equity
$17.33M
As of 2025-07-31
$23.41M
As of 2026-04-30
+18.8%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-07-31 | $17.33M | n/m | 2025-10-16, Balance as of period end |
| 2024-07-31 | -$2.68M | n/m | 2025-10-16, Balance as of period end |
| 2023-07-31 | -$3.78M | n/m | 2024-10-29, Balance as of period end |
| 2022-07-31 | $10.33M | -62.7% | 2023-10-25, Balance as of period end |
| 2021-07-31 | $27.67M | n/a | 2022-10-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| BriaCell Therapeutics Corp. (BCTX) | 2025-07-31 | $17.33M | n/m |
| Phio Pharmaceuticals Corp. (PHIO) | 2025-12-31 | $20.15M | +326.6% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | -$63.61M | n/m |
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $15.01M | +33.9% |
| Annovis Bio, Inc. (ANVS) | 2025-12-31 | $16.85M | +81.0% |
| Abvc Biopharma, Inc. (ABVC) | 2025-12-31 | $11.11M | +806.2% |
| Jyong Biotech Ltd. (MENS) | 2025-12-31 | -$24.91M | n/m |
| Gain Therapeutics, Inc. (GANX) | 2025-12-31 | $18.56M | +152.9% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $18.22M | -53.5% |
Compare BCTX, PHIO, EMMA, MBRX side by side · Screen every company in Pharmaceutical Preparations ↗